financetom
Business
financetom
/
Business
/
Update: Walgreens Boots Alliance Shares Jump After Fiscal Q4 Adjusted Earnings, Sales Top Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Walgreens Boots Alliance Shares Jump After Fiscal Q4 Adjusted Earnings, Sales Top Estimates
Oct 15, 2024 10:04 AM

12:41 PM EDT, 10/15/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph.)

Walgreens Boots Alliance ( WBA ) shares jumped nearly 13% in recent trading on Tuesday after the company posted fiscal Q4 adjusted earnings and sales ahead of consensus.

The company reported fiscal Q4 adjusted net earnings of $0.39 per diluted share, down from $0.67 a year earlier.

Analysts polled by Capital IQ expected $0.36.

Sales for the quarter ended Aug. 31 were $37.55 billion, up from $35.42 billion a year earlier.

Analysts surveyed by Capital IQ expected $35.55 billion.

For fiscal 2025, the company expects adjusted EPS in the range of $1.40 to $1.80. Analysts polled by Capital IQ expect $1.83.

Sales for the fiscal year are expected in the range of $147 billion to $151 billion. Analysts surveyed by Capital IQ expect $147.48 billion.

Additionally, Walgreens Boots Alliance ( WBA ) announced it aims to close about 1,200 stores over the next three years, with around 500 closures planned for fiscal 2025. The initiative is expected to be "immediately accretive to adjusted EPS and free cash flow," the company said.

The plan includes about 300 store closures in a previously approved plan.

Price: 10.15, Change: +1.15, Percent Change: +12.72

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Corbus Pharma Q3 net loss widens to $23.3 mln
Corbus Pharma Q3 net loss widens to $23.3 mln
Nov 12, 2025
Overview * Corbus Pharmaceuticals ( CRBP ) Q3 net loss widens to $23.3 mln, driven by clinical development costs * Company completed $75 mln public offering, extending cash runway into 2028 * CRB-701 clinical data shows promising ORR in HNSCC, cervical, and bladder cancers Outlook * Company plans to meet FDA in Q1 2026 for CRB-701 data review * Corbus...
Coya Therapeutics' Q3 net loss narrows
Coya Therapeutics' Q3 net loss narrows
Nov 12, 2025
Overview * Coya Therapeutics ( COYA ) Q3 net loss narrows to $2.1 mln from $4.0 mln last year * Company reports $3.6 mln collaboration revenue due to IND approval milestone * Coya completes $23 mln public offering, extending cash runway into 2H 2027 Outlook * Company expects to receive $4.2 mln milestone payment upon first patient dosing in ALS...
Cypherpunk Technologies' Q3 net loss narrows
Cypherpunk Technologies' Q3 net loss narrows
Nov 12, 2025
Overview * Cypherpunk Technologies reports Q3 net loss of $3.3 mln, down from $18.2 mln last year * Company acquires 203,775 ZEC for $50 mln as part of digital asset strategy * Closed $58.88 mln private placement led by Winklevoss Capital for digital asset strategy Outlook * Company did not provide specific financial guidance for future quarters or year Result...
Apparel retailer LightInTheBox Q3 net income jumps, revenue drops on margin focus
Apparel retailer LightInTheBox Q3 net income jumps, revenue drops on margin focus
Nov 12, 2025
Overview * LightInTheBox ( LITB ) Q3 net income rises to $2.8 mln from $0.3 mln last year * Company Q3 revenue declines 3% yr/yr, reflecting focus on margin preservation * Gross margin improves to 66.9% from 61.1% last year, driven by high-margin products Outlook * LightInTheBox ( LITB ) expects overall revenue growth in 2026 * Company plans broader...
Copyright 2023-2026 - www.financetom.com All Rights Reserved